Cardiovascular disease is the number one killer in UK and in most of the Western countries. It is already a huge burden to healthcare systems around the world, and improvements in the prevention, diagnosis, and effective treatment will be among the most pressing challenges within our aging populations in this century.
We will transform Cambridge into a world-leading hub for cardiovascular research. The foundation for this is provided through the integration of high quality pre-clinical and clinical research operating in a University-Hospital-Industry partnership. This partnership will be driven by the re-location of the Royal Papworth hospital and AstraZeneca global HQ and R&D facilities to the Cambridge Biomedical Campus, and will be further strengthened by the foundation of a dedicated Heart & Lung Research Institute (opened in July 2022) and renamed the Victor Phillip Dahdaleh Heart and Lung Research Institute in 2023.